Abstract: The present invention relates to a polyvalent culture medium for anaerobic bacteria under aerobic conditions in blood culture bottles. The present invention provides a polyvalent culture medium for culture in aerobic atmosphere of anaerobic bacteria or aerobic bacteria comprising a basal culture medium for bacteria characterized in that it further comprises a mixture of the following antioxidant compounds: sodium hydrosulphide (Na2S), L-cysteine, ascorbic acid, glutathione, catalase, ubiquinol and lipoic acid.

Abstract: The present invention relates to a composition comprising polyclonal antibodies directed against human cells, wherein the said polyclonal antibodies are devoid of a first antigenic determinant selected in a group comprising (i) N-glycol-neuraminic acid (Neu5Gc) and (ii) ?-1,3-galactose and its use as a medicament.

Abstract: The present invention relates to mutated factor (FX) polypeptides and uses thereof for the treatment of haemophilia. In particular, the present invention relates to a mutated factor X (FX) polypeptide which comprises a heavy chain wherein at least one amino acid residue at position 401 or 408 is mutated.

Abstract: The invention relates to a method for determining active concentrations of an analyte and optionally kinetic constants for the interaction of the analyte with a ligand in complex biological samples by means of surface plasmon resonance comprising the use of an auto-blank.

Abstract: Disclosed is a method for pattern recognition in a plurality of received time signals of different types, the method includes: b) for each received signal, creating an asynchronous time signal including events; c) for each created asynchronous signal, creating an activity profile of the asynchronous signal which decreases as a function of the time elapsed since the last event of the asynchronous signal; d) for a given time t0: d1) determining a context defined as the set of activity profiles of the created asynchronous signals, d2) determining a standard context among predetermined standard contexts, having a minimum distance to the context determined in step d1, d3) determining the pattern as a function of the determined standard context.

Abstract: The present invention relates to T-cell receptors (TCR) that recognize pancreatic betacell epitopes and uses thereof for the diagnosis and treatment of diabetes.

Abstract: The present invention relates to methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer. In particular, the present invention relates to a method of enhancing the CD8+ T cell-dependent immune response in a subject suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent capable of increasing intra-tumoral ceramide content.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of acute myeloid leukemia. In particular, the present invention relates to a method for treating NPM-1-driven acute myeloid leukemia (AML) in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one arsenic compound and with a therapeutically effective amount of at least one retinoid.

Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.

Abstract: A method for printing uses at least one bio-ink. The method also uses at least one laser print head to deposit at least one droplet of at least one bio-ink onto a depositing surface of a receiving substrate. The printing method uses at least one nozzle print head to deposit at least one droplet of at least one bio-ink onto a depositing surface of the same receiving substrate as the laser print head.

Abstract: Disclosed are agents inhibiting the interaction between CFH and CD11b/18, as well as the use of such agents, in particular for treating inflammatory disorders, such as age-related macular degeneration.

Abstract: The present invention relates to the field of cardiology and, more specifically, to a novel algorithm that can be used, in particular, in a method for determining if a drug is likely to induce a cardiac ventricular repolarisation disturbance, based on variations in electrocardiogram data.

Abstract: The invention relates to constructs, vectors, relative host cells and pharmaceutical compositions which allow an effective gene therapy, in particular of genes larger than 5 Kb by using an improved hybrid dual recombinant AAV vector system.

Abstract: The present invention concerns a compound of formula (I), or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.

Abstract: Disclosed is a method for assistance with the establishment of a diagnosis of a patient, starting from at least one identified sign, and based on a computerized knowledge database including a medical ontology. The medical ontology includes: a list of signs forming a “sign” class; a list of pathological states forming a “pathological state” class; and a first set of logical relationships between the signs and the pathological states, each logical relationship establishing a correlative link between a sign and a pathological state. The method includes: a step of searching for potential pathological states, linked to at least one of the identified signs by the first set of logical relationships; and a step of identifying potential signs in which, for each potential pathological state, all of the signs linked by a correlative link to the potential pathological state are identified by the first set of logical relationships.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of systemic mastocytosis. The inventors showed the effect of KPT-251 treatment on SCF-dependent human Mast cell (MC) line without KIT mutation (WT ROSA) and on two factor-independent MC lines with KIT mutations : ROSA ? 417-419 insY and ROSA D816V. KPT is a Selective Inhibitor of Nuclear Export (SINE) that specifically inhibits the activity of the exportin-1 (XPO1). KPT-251 treatment induces minimal toxicity in non-cancerous hematopoietic cells both in vitro and in vivo. In particular, the present invention relates a method of treating systemic mastocytosis in patient in need thereof comprising administering to the patient a therapeutically effective amount of a XPO1 inhibitor.

Abstract: The invention relates to a method for inducing human cholangiocyte differentiation of progenitor cells called hepatoblasts. More specifically, the invention relates to a method for differentiating hepatoblasts to cholangiocytes by culturing said hepatoblasts with a particular medium having interleukin-6 (IL-6) activity. The differentiation method can specifically induce cholangiocyte differentiation from hepatoblasts, and the human cholangiocytes differentiated according to the invention may be useful for drug discovery for treatment of cholangiopathies and bioengineered livers.

Abstract: The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.

Abstract: The present Inventors demonstrated that the RelB subunit of NF?B plays a crucial role in promoting cell migration. More precisely, they identified that this pro-migratory activity is mediated by the activation of the NF?B pathway through RelB phosphorylation at serine 472. In a first aspect, the present invention proposes to monitor the activation of the NF?B pathway by following the phosphorylation status of said serine. Also, the present invention discloses methods and kits for prognosing the evolution of a disease involving cell migration in a subject—treated or not—suffering thereof, based on the detection of said RelB-S472 phosphorylation.

Abstract: The disclosure is directed at providing molecular tools and methods for transgenes integration in the genome of host cells, in particular tools and method enabling a transposition-dependent expression of the transgene, thereby facilitating identification and selection of effectively transformed hosts.